Marylore Chenel

pekerjaan: peneliti

Seri

There is nothing here

Create a new serie

Karya

There is nothing here

Create a new work

Artikel 43

Date

Judul

Pengarang

2021-10-28

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

Marylore Chenel
2020-05-25

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

Philippe B Pierrillas, Marylore Chenel
2020-07-19

Quantitative Systems Pharmacology approaches for Immuno-oncology: adding virtual patients to the development paradigm

Marylore Chenel
2020-08-05

Impact of interleukin-6 on drug transporters and permeability in the hCMEC/D3 blood-brain barrier model

Florian Simon, Marylore Chenel
2020-10-08

Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method

Marylore Chenel
2020-12-07

Impact of hepatic CYP3A4 ontogeny functions on DDI risk in paediatric PBPK/PD modelling: critical literature review and ivabradine case study

Marylore Chenel
2019-11-10

Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development

Neeraj Gupta, Ulrika S H Simonsson, Cynthia J Musante, Marylore Chenel
2019-11-12

Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder

Marc Cerou, Marylore Chenel
2019-12-20

Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal Cells

Léa Payen, Marylore Chenel
2019-04-02

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy

Marylore Chenel
2018-02-20

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART® Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.

Jean-Michel Scherrmann, Marylore Chenel
2018-01-13

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use.

Marylore Chenel
2018-03-07

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Andrew C. Hooker, Marylore Chenel, Mats O Karlsson
2018-03-27

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Andrew C. Hooker, Marylore Chenel, Mats O Karlsson
2018-09-18

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice

Marylore Chenel
2017-05-24

Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling

Marylore Chenel
2017-06-23

Model Description Language (MDL): A Standard for Modeling and Simulation

Andrew C. Hooker, Florent Yvon, Zinnia P Parra-Guillen, Niklas Hartung, Marylore Chenel, Mats O Karlsson
2016-01-12

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors

Marylore Chenel
2016-06-21

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes

Marylore Chenel
2015-02-20

Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates

Julie Bertrand, Marylore Chenel
2015-11-14

Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment

Marylore Chenel
2015-11-12

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Marylore Chenel
2014-05-31

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

Melanie White-Koning, Etienne Chatelut, Marylore Chenel
2014-03-18

Development of a physiologically-based pharmacokinetic model of the rat central nervous system

Raj K S Badhan, Marylore Chenel
2014-01-01

Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics

Marylore Chenel
2013-06-05

Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor

Etienne Chatelut, Marylore Chenel
2013-06-18

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Jean-Charles Soria, Antoine Hollebecque
2013-03-30

A physiologically based pharmacokinetic model for strontium exposure in rat.

Marylore Chenel
2013-01-01

Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information

Marylore Chenel
2013-07-25

Influence of the duration of intravenous drug administration on tumor uptake

Marylore Chenel
2011-11-03

Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models

Julie Bertrand, Marylore Chenel
2011-05-27

Development of a complex parent-metabolite joint population pharmacokinetic model

Julie Bertrand, Marylore Chenel

Human - wd:Q114435407

Selamat datang di Inventaire

perpustakaan teman-teman dan komunitas anda

pelajari lebih lanjut